Congenital coagulation disorders limit the use of liver biopsy, especially when repeated assessment is needed. TGF-beta 1 plays a pivotal role in inducing fibrosis and has been proposed as its surrogate marker. Aiming at validating the clinical utility of this cytokine, fifteen haemophilic patients suffering from HCV-related chronic hepatitis were treated with Peg-IFN alpha2~plus Ribavirin. Serum TGFbeta 1, viral load and liver enzymes were analyzed at baseline and at six, twelve, and eighteen months. As expected, patients initially showed significantly higher TGF-beta 1 levels than age-matched controls (43.8 ng/mL, 28.7-46.4 vs. 26.9 ng/mL, 23.0-34.0, median and 95% CI; p=0.004). The end of therapy response rate was 67%. The main finding was a significant drop in TGF-beta 1 at six months compared to baseline values; this drop de facto predicted the levels reached in the following six months, which were fixed at lower concentrations (37.0 ng/mL, 21.9-43.8 and 27.0 ng/mL, 24.1-44.0 respectively; p<0.009), independently oftreatment outcome (three patients were breakthrough, twelve were sustained virological responders (SVRs). During the treatment period none had clinical or biochemical signs of inflammation in other areas. Treatment was followed by a six-month follow-up, at the end of which TGF-beta 1 was increased compared to the previous values, reaching the initial levels in ten SVRs (45 ng/mL, 24.5-52.9).
Congenital coagulation disorders limit the use of liver biopsy, especially when repeated assessment is needed. TGF-beta 1 plays a pivotal role in inducing fibrosis and has been proposed as its surrogate marker. Aiming at validating the clinical utility of this cytokine, fifteen haemophilic patients suffering from HCV-related chronic hepatitis were treated with Peg-IFN alpha2~plus Ribavirin. Serum TGFbeta 1, viral load and liver enzymes were analyzed at baseline and at six, twelve, and eighteen months. As expected, patients initially showed significantly higher TGF-beta 1 levels than age-matched controls (43.8 ng/mL, 28.7-46.4 vs. 26.9 ng/mL, 23.0-34.0, median and 95% CI; p=0.004). The end of therapy response rate was 67%. The main finding was a significant drop in TGF-beta 1 at six months compared to baseline values; this drop de facto predicted the levels reached in the following six months, which were fixed at lower concentrations (37.0 ng/mL, 21.9-43.8 and 27.0 ng/mL, 24.1-44.0 respectively; p<0.009), independently oftreatment outcome (three patients were breakthrough, twelve were sustained virological responders (SVRs). During the treatment period none had clinical or biochemical signs of inflammation in other areas. Treatment was followed by a six-month follow-up, at the end of which TGF-beta 1 was increased compared to the previous values, reaching the initial levels in ten SVRs (45 ng/mL, 24.5-52.9). Interestingly, at a longer follow-up, two out often SVRs, who displayed the highest values ofTGF-beta 1, relapsed. Serum TGF-beta 1 could be used to assess therapeutic outcome and short-term prognosis of HCV-related chronic hepatitis.
Prior to the introduction of virally inactivated clotting factor concentrates in the mid '80's, the majority of individuals with congenital bleeding disorders who received plasma-derived products became infected with Hepatitis C Virus (HCV). Although HCV infection in haemophiliacs may be less severe than in HCV infected patients without haemophilia (1), with longer duration of HCV infection, the risk of developing end-stage liver disease is emerging (2) . Only Percutaneous Liver Biopsy (PLB) is a reliable method that defines prognosis of chronic hepatis C by staging the extent of Hepatic Fibrosis (HF). PLB is an invasive but safe procedure in patients with inherited bleeding disorders when the coagulation disorder is fully corrected (3) . PLB is valuable also in guiding antiviral therapy. In fact, the therapeutic efficacy is weighted by evaluating the ALanine aminoTransferase (ALT) value normalization, the serum HCV-RNA clearance and mainly improvement or stability of the histological features. However, there is a reluctance to perform PLB in this population because of the risk of bleeding. For this reason, the authorities have approved transjugular liver biopsy safety and usefulness in this patient population (4), even though some limitations on the adequacy of samples are present. However, ethical reasons and health care costs limit its use, mainly when patients are asked to repeat the procedure after antiviral therapy. Some recently discovered serum substances mirroring liver fibrosis have been proposed as serologic surrogate markers, also in hemophiliacs (5) . Of these, Fibro Test has gained a certain acceptance (6) . Finally, transient elastography, being absolutely non-invasive, has recently been recommended as an alternative to PLB, especially in patients with bleeding tendency (7) . This instrument, however, suffers from some weaknesses, expressing its best potential in diagnosing advanced liver fibrosis (8) .
In the liver, Transforming Growth Factor-beta 1 (TGF-beta 1) stimulates the expression of extracellular matrix components, inhibits collagenase components, and promotes the activation of fat-storing haematopoietic stem cells towards a myofibroblast phenotype. TGF-beta I, measurable in serum, urine and tissue specimens, has been shown to be raised in HCV infection (9-10) and to correlate with clinical/histological severity of HF (10); therefore, its levels have been proposed as a potential marker of antiviral-induced reduction of HF (10) . Aiming at validating the clinical utility of this cytokine as parameter of response, a population of haemophilic patients with HCV-related chronic hepatitis was studied before and long after exposure to antiviral drugs.
MATERIALS AND METHODS

Patient Selection
Thirty-four treatment-naive adult haemophilic patients were characterized by serum HCY-RNA presence, detectable by Polymerase Chain Reaction (PCR). The patients were required to have had elevated ALT levels at least once during the 6 months prior to screening. Patients, who accepted to be cured and adhere to the therapeutic protocol, refusing to undergo liver biopsy, were eligible to be enrolled into the study. Exclusion criteria included positivity for serum hepatitis B surface antigen or Human Immunodeficiency Virus (HIY) infection, decompensated liver disease, neutrophil count less than 1,500 cells/rum', platelet count less than 70,000 cells/mm', haemoglobin levels less than 13 g/dL, poorly controlled psychiatric disease, history of substance abuse (such as alcohol, intravenous or inhaled drugs) within 6 months of study entry, history of coexisting medical conditions of inflammatory nature that could interfere with the study.
Study Design
Fifteen haemophilic patients (Table I) suffering from naive HCY-related chronic hepatitis, with different genotypes (1/4) and high viral replication, were treated with combined antiviral therapy (Peg-IFN alpha2b 1.5 meg/Kg body weight/week plus Ribavirin at standard doses of 800-1200 mg on the body weight basis for twelve months). Because we managed data from patients who completed the therapy, the intention-to-treat analysis was not performed.
Assessment and End Points
Testing for HCY-RNA was performed using quantitative real-time PCR with a lower and upper limit of detection of 600 IU/mL (Amplicor method -Roche Mol. Diagn., Milan, Italy) and 600,000 IU/mL, respectively. HCY genotyping was performed adopting Bayer's YERSANT HCY Genotype 1.0 Assay (LiPA). High sensitivity C-Reactive Protein (hs-CRP) was dosed by an enzyme immunoassay kit (BioCheck, Inc, Foster City, CA, USA). TGF-beta 1 was dosed by using a Quantikine immunoassay kit (R&D Systems, Inc. Minneapolis, MN USA). The mean minimum detectable on eight samples was 4.87 pg/mL. The intraassay and inter-assay precision coefficient variation (%) was 3.4 and 8.4, respectively. Serum TGF-beta I concentration, contextually with HCY viral load and liver enzymes, i.e. ALT, was analyzed at zero, 6, 12, and 18 months. The primary efficacy analysis was evaluated assessing rates of response among all patients. End-of-Treatment Response (ETR) was defined as the absence of detectable serum HCY-RNA at 48 weeks, and Sustained Virological Responders (SYRs) all those kept the absence of detectable serum HCY-RNA 24 weeks after treatment completion. Relapsers were those individuals having undetectable HCY-RNA at the end of treatment and reappearance of HCY-RNA during the 24 weeks after treatment, while breakthrough was the loss of virological response during therapy. The follow-up period lasted more than twelve months after therapy cessation.
Statistics
Paired Wilcoxon test compared the rank values of the serum TGF-beta 1 in the well-matched groups, and before and after therapy. Repeated ANOYA measures were adopted to follow the behaviour of the same cytokine during the study period in the same patients. Systat 12 was the statistical package used. did not undergo liver biopsy. Thus, lacking this information, its behaviour could not correspond to the histological features found in other studies on HCV-related chronic hepatitis patients, showing a reduction of the fibrosis score in responders and, sometimes, in non-responders (16) . Furthermore, given the current concept that fibrosis is a dynamic rather than a static process (17) , extra-cellular matrix is constantly produced and reabsorbed, and the progressive accumulation offibrous tissue is thought to represent a relative imbalance between profibrotic and anti-fibrotic processes -serum TGF-beta 1 values probably mirror the new cytokine-induced fibrogenesis rather than the stable HF.
Accordingly, the constantly negative HCV-RNA serum values in SVR may not necessarily represent a good parameter to infer an amelioration of chronic hepatitis. It has been hypothesized that in treated patients with SVR small quantities of HCV-RNA may persist for months or years in peripheral blood mononuclear cells or liver tissue (18) . These findings are important because they bring into question the current definition of SVR. Our TGF-beta 1 data may reflect the persistence of virus and its implications on future disease progression, disease activation and the development or persistence of hepatic fibrosis. The de novo increase in serum TGF-beta 1 levels after the end of therapy in the absence of ---,----------------------------------- Table I . As expected, patients initially showed significantly higher TGF-beta 1 levels than the 15 age-matched controls (43.8 ng/mL, 28.7-46.4 vs. 26.9 ng/mL, 23.0-34.0, median and 95% CI; p=0.004; paired Wilcoxon test). Surprisingly, the ETR rate was high, assessing to 67%. The main finding was a significant drop' in TGF-beta 1 at six months compared to initial values; this drop de facto predicted the levels reached at the following 12 month-period, which were fixed at lower concentrations (37.0 ng/mL, 21.9-43.8 and 27.0 ng/mL, 24.1-44.0 respectively; p<0.009, repeated ANOVA measures; Fig. 1 ), independently of treatment outcome (12 patients were SVR, 3 patients were breakthrough; Table II ). The breakthrough event arose between the sixth and the ninth month; however, all the patients were asked to complete the therapy schedule.
At time ofevaluations none had significant clinical or biohumoral (hs-CRP) signs of inflammation in other areas. Treatment was followed by a six-monthfollow-up, at the end of which TGF-beta 1 were increased compared to the previous values, reaching the initial levels in 10 SVR (45 ng/mL, 24.5-52.9; paired Wilcoxon test).
Interestingly, at a longer follow-up (12 months) two out of 10 SVRs, who displayed the highest values of TGF-beta I, relapsed. Surprisingly, no major bleeding event was registered during antiviral schedule, and the need of clotting factor replacement was diminished.
RESULTS
DISCUSSION
.Recent evidence of literature show that levels of TGF-beta I are significantly lower in subjects suffering from chronic hepatitis C who have not developed fibrosis (10) (11) (12) (13) (14) . In addition, the induction of this sustained pro-fibrotic signal by HIV may cause accelerated liver fibrosis during H(:VIHIV coinfection (15) . However, we are not able to confirm that serum TGF-beta 1 concentrations may be used as surrogate marker of HF because our patients inflammatory signs is probably due to the lack of definitive clearance of HCY-RNA and could predict an ongoing HF. Another attractive point to speculate is the fact that the antiviral course should be longer so as to induce a more stable reduction ofTGF-beta 1 by consolidation therapy (19) . Interestingly, the marked reduction ofserum TGFbeta 1 during the antiviral therapy, irrespective of final viral load, could be due to a series ofboth direct and indirect mechanisms, including the inhibition of collagen promoter transcription in hepatic stellate cells by IFN-a (20) , and the down-regulation of HCY-specific parenchimal cells producing TGF-beta 1, at least partially secondary to reduced amount of antigenic trigger (9, 21) ; thus, the behaviour ofTGF-beta 1 levels on antiviral treatment is likely to mirror the lowering of cytokine-induced fibrogenesis.
Then, TGF-beta 1 could provide a more accurate picture of the dynamic process leading to liver fibrosis, allowing us to gain information for treatment decision-making and follow-up of antiviral therapy.
In conclusion, high serum TGF-beta 1 concentrations may show the host's disability to mount an effective HCY-specific immune response and could foresee the persistence of HCY infection. Congenital coagulation disorders somehow limit the ordinary use ofliver biopsy and, on this basis, the serum TGF-beta 1 determination could be employed to monitor the shortterm prognosis, perhaps better than other laboratory parameters (viral and enzymatic).
